Heda Zhang

Dr. Heda Zhang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HZHeda Zhang
Heda Zhang
DSDa-Wei Sun
Da-Wei Sun
LMLing Mao
Ling Mao
JZJun Zhang
Jun Zhang
LJLin-Hong Jiang
Lin-Hong Jiang
THTang Jin Hai
Tang Jin Hai

19 February 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
HZHeda Zhang
Heda Zhang
LJLin-Hong Jiang
Lin-Hong Jiang
DSDa-Wei Sun
Da-Wei Sun
JLJian Li
Jian Li
JTJin-Hai Tang
Jin-Hai Tang

19 December 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SZShanliang Zhong
Shanliang Zhong
HXhanzi xu
hanzi xu
DWDandan Wang
Dandan Wang
SYSujin Yang
Sujin Yang
HLHuixin Li
Huixin Li
SZSiying Zhou
Siying Zhou

26 July 2024 in Aging
Verified
Journal Article
Open access
PDF file
DWDan-Dan Wang
Dan-Dan Wang
LLLei Li
Lei Li
YFYu-Qi Fu
Yu-Qi Fu
SYSu-Jin Yang
Su-Jin Yang
XCXiu Chen
Xiu Chen
HZHeda Zhang
Heda Zhang
Background: The expression patterns and prognostic value of Procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD) family genes in breast cancer remain to be elucidated. Methods: The expression levels, prognostic value, and biological function of PLODs were determined using Oncomine, cBioPortal, GEPIA, Timer, UALCAN, PrognoScan, GeneMANIA, Metascape, and breast cancer tissue microarrays. Results: The expressions of PLOD1 and PLOD3 were upregulated in breast cancer tissues, indicating worse clinical stages. High expression levels of PLOD family genes were associated with worse disease-free survival and distant metastasis-free survival, while high expression levels of PLOD1 and PLOD3 were related to worse overall survival in all breast cancer patients. The levels of PLOD family genes were all significantly higher in the age ≤51 y group, HR-negative patients, and triple negative breast cancer (TNBC) patients. They are associated with tumor-infiltrating immune cells (TIICs), including CD4+ T cells, CD8+ T cells, B cells, macrophages, neutrophils, and dendritic cells. According to co-expression gene analysis and functional enrichment, they are associated with protein hydroxylation, collagen biosynthesis and modifying enzymes, collagen metabolism, RNA splicing, extracellular matrix organization, VEGFA-VEGFR2 signaling pathway, and skeletal system development. Immunohistochemistry showed that the expressions of all PLOD family genes were significantly elevated in breast cancer tissues. PLOD1 expression was positively correlated with ER, TNBC status, and tumor grade. PLOD2 expression was positively connected with Ki-67 status. PLOD3 expression was positively related with age and tumor grade. Conclusions: PLOD family genes are novel potential prognostic biomarkers for breast cancer, and targeting PLOD inhibitors might be an effective strategy for breast cancer therapy.

11 September 2024 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
DWDan-Dan Wang
Dan-Dan Wang
LJLin-Hong Jiang
Lin-Hong Jiang
JZJian Zhang
Jian Zhang
XCXiu Chen
Xiu Chen
HZHong-Lei Zhou
Hong-Lei Zhou
HZHeda Zhang
Heda Zhang
To investigate the relationship between the expression of androgen receptor (AR) and clinical characteristics in breast cancer. The clinical records of all 432 patients tested for AR in our institution between January 2020 and May 2023 were reviewed. Clinical characteristics, age, menopausal status, tumor node metastasis (TNM) stage, distant metastasis, pathological complete response (pCR), histopathological features histological grade, estrogen receptor (ER), progesterone receptor, Her-2, Ki-67, and molecular subtype were registered for all patients. About 377 (87.27%) of the 432 patients had AR expression. No significant difference in AR expression was found with age, menopausal status, TNM stage of primary tumor, or pCR. AR was positively and significantly associated with the histological grade, and recurrence. The AR expression was significantly related with molecular subtypes, including ER, PR Her-2, Ki67 and molecular subtype. ER (OR = 10.489, 95%CI: 5.470–21.569), PR (OR = 7.690, 95%CI: 3.974–16.129, Her-2 (OR = 10.489, 95%CI: 2.779–23.490 and tumor recurrence (OR = 0.110, 95%CI: 0.031–0.377 were significant independent risk factors affecting AR expression. AR expression can serve as a reliable basis for judging the clinical molecular types and poor prognosis for breast cancer. AR may be a novel biomarker and target in AR-positive breast cancer depending on significant difference in AR expression among different molecular types of breast cancer.

1 January 2022
Verified
Closed access
DWDandan Wang
Dandan Wang
JZJian Zhang
Jian Zhang
LJLinhong Jiang
Linhong Jiang
XCXiu Chen
Xiu Chen
SYSujin Yang
Sujin Yang
HZHeda Zhang
Heda Zhang